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PMH6
ANTIPSYCHOTIC TREATMENT AND DIABETES IN A
PRIVATELY INSURED POPULATION
Zhao Z, Loosbrock D, Cooper LM
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Assess diabetes incidence for individuals treated
with antipsychotics. METHODS: Medical/pharmacy claims
from a large insured population were analyzed to identify 5631
individuals initiated on typical (n = 2326) or atypical (n = 3305)
antipsychotics between October 1, 1996 and December 31,
1998; had no antipsychotic use; had no diabetes diagnosis and/or
antidiabetic use in the year prior. Patients were followed to the
ﬁrst event including: new-onset diabetes; antipsychotic augmen-
tation/switch/discontinuation; insurance disenrollment; end of
the data. Diabetes was deﬁned as receiving two diabetes diag-
noses (ICD9-CM: 250.xx) and/or one antidiabetic prescription.
Additionally, incidence of treated diabetes (received antidiabetic
prescription) was examined. Cox proportional hazard models
were used to compare the hazard ratios (HR), controlling for
potential confounding factors. RESULTS: Crude diabetes inci-
dence was 1.76% and 1.97% for typical and atypical cohorts,
respectively (2.04% and 1.95% for olanzapine- and risperidone-
treated patients, respectively). Rates of treated diabetes were
1.72% for typical and 1.94% for atypical cohorts; 1.95% for
both olanzapine and risperidone cohorts. Among the treatment
groups, adjusted HR (95% conﬁdence interval): atypical-
versus-typical: 1.13 (0.75–1.69); olanzapine-versus-typical: 1.14
(0.67–1.95); risperidone-versus-typical: 1.12 (0.72–1.75); and
olanzapine-versus-risperidone: 0.96 (0.56–1.65). Similar results
were observed for treated diabetes incidence. CONCLUSION:
Diabetes incidence was not statistically signiﬁcantly different for
atypical versus typical, although typical-treated patients had
numerically lower incidence. There was no signiﬁcant difference
between olanzapine and risperidone.
PMH7
TREATMENT AND ECONOMIC OUTCOMES IN PEDIATRIC
INPATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS
Flanders S1, Pandina G1, Rupnow M1, Jensik S2
1Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA; 2Mental
Health Outcomes, Inc., Lewisville,TX, USA
OBJECTIVES: To compare treatment outcomes, by the Brief
Psychiatric Rating Scale for Children (BPRS-C), and length of
stay (LOS) for a group of child and adolescent psychiatric inpa-
tients who were prescribed an atypical antipsychotic (AA) to
those not prescribed an AA at discharge. METHODS: Data 
was collected from 48 facilities across the United States between
July, 1999 and June, 2003. Descriptive statistics, ANOVA, and
ANCOVA were used to compare differences between and within
a group that was prescribed an AA (risperidone, olanzapine or
quetiapine) (n = 1131) and a group that had not been prescribed
AA at discharge (n = 1741). RESULTS: Inpatients were between
4–17 years old. Most patients were Caucasian, male, suffered
from their disorders between 2–3 years, and lived at home 
with family prior to admission. At admission, the AA treatment
group showed greater difﬁculty with respect to BPRS-C overall
score (p < 0.001); however at discharge, patients given AA
showed greater improvement in BPRS-C subscores of behavior
problems, thinking disturbances, and psychomotor excitation (p
< 0.03), but less improvement in the depression subscore than
patients given no antipsychotic (p < 0.02). Average daily dosage
at discharge was 2.3mg for risperidone, 156.3mg for quetiap-
ine, and 9.6mg for olanzapine. After adjusting for covariates,
AA patients had a longer LOS (26.4 v. 22.4 days) than patients
given no antipsychotic (p = 0.017). AA patients treated with
risperidone had signiﬁcantly shorter LOS (17.3 days) than those
treated with quetiapine (24.3 days) or olanzapine (28.1 days) (p
= 0.024). CONCLUSIONS: Child and adolescent inpatients
receiving AA had more signiﬁcant emotional and behavioral dis-
orders at admission than those not prescribed an AA. The AA
treatment group showed greater improvement in behavior 
problems, thinking disturbances, and psychomotor excitation
outcomes than patients given no antipsychotic, but less improve-
ment in depressive symptoms. Among AA treated patients, 
LOS was signiﬁcantly shorter for inpatients treated with 
risperidone.
PMH8
SWITCHING & DISCONTINUATION OF SERTRALINE,
PAROXETINE AND CITALOPRAM THERAPY
Wang J1, Mullins CD1, Shaya FT1, Meng F1, Harrison DJ2
1University of Maryland, Baltimore, MD, USA; 2Pﬁzer, Inc, New York,
NY, USA
OBJECTIVES: Patient adherence is critical for successful man-
agement of mental illnesses. This study compares adherence 
rates across branded selective serotonin reuptake inhibitors.
METHODS: This retrospective cohort study used an adminis-
trative database between January 1, 1999 and June 30, 2002.
Adherence status was categorized into persistence, switching 
and discontinuation. Persistence was deﬁned based on the days
supply, with a minimum of 15 days to reﬁll. Survival analyses
were conducted. Age, gender, and co-payment were included as
covariates in Cox proportional models. Sensitivity analyses were
performed to determine the sensitivity of the algorithm for deter-
mining adherence. RESULTS: Compared with sertraline patients
(N = 5598), those on paroxetine (N = 5204) had lower persis-
tence rates (23.8% vs. 26.0%, P = 0.0093), higher switching
(3.6% vs. 3.3%, P = 0.5076) and discontinuation rates (72.7%
vs. 70.7%, P = 0.0258). Survival curves showed that the persis-
tence rates for sertraline patients were signiﬁcantly greater than
for paroxetine (P < 0.05, Log-Rank and Wilcoxon tests), while
similar to those for citalopram patients (N = 4131). Age and
gender were independent predictors of persistence, while co-
payment was not. These ﬁndings were consistent across a broad
variety of deﬁnitions of persistence by varying the allowed time
to reﬁll. CONCLUSIONS: Paroxetine patients were signiﬁcantly
more likely to discontinue therapy than either sertraline or citalo-
pram patients.
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